NASDAQ:NVCN Neovasc (NVCN) Stock Price, News & Analysis → A new way to collect income from stocks (From DTI) (Ad) Free NVCN Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$30.03▼$30.0350-Day Range$29.03▼$30.0352-Week Range$4.59▼$30.07Volume1 shsAverage Volume56,993 shsMarket Capitalization$82.28 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Neovasc alerts: Email Address Ad Insiders ExposedThe Hard Truth About Investing For RetirementHere’s the cold, hard truth about investing: The more capital you have, the more risk averse you can afford to be. But when you’re staring down the barrel of retirement and you’ve only got 5, 10, 50 or $100,000 saved, you’ve got to be more aggressive. In an exclusive online training, the Market expert Steven Place is revealing a powerful “roadmap” that’s leading everyday investors to easy, triple-digit wins, even if they don’t have a lot of experience in trading.Click To Access This Powerful Training Right Now! About Neovasc Stock (NASDAQ:NVCN)Neovasc, Inc. engages in the development, manufacture and marketing of medical devices. It focuses on Neovast Tiara and Neovasc Reducer products. The company was founded on November 2, 2000 and is headquartered in Richmond, Canada.Read More Ad WealthPress$25,000 into $109,616 in two months? Today I want to show you how our research shows you could’ve grown a $25,000 account into $109,616.12 within the last TWO months. You see, former multi-million dollar hedge fund manager Roger Scott spent the better half of 2023 developing what might be the most advanced trading tool that exists… It’s a revolutionary software system that tracks the moves of institutional investors…. in real time…Go here to watch the most recent trading workshop video at no charge. NVCN Stock News HeadlinesApril 15, 2023 | theglobeandmail.comClosing Bell: Neovasc Inc down on Tuesday (NVCN)April 11, 2023 | theglobeandmail.comClosing Bell: Neovasc Inc up on Monday (NVCN)April 25, 2024 | Banyan Hill Publishing (Ad)The Best AI Stock to Own in the World Today is Trading for Just $25“Titan of Tech” Bets Big on Tiny AI Company He’s made as much as 3,250,000% in just three years on companies like Facebook, Airbnb, and PayPal… But our research shows his latest investment could be his most successful venture yet.March 31, 2023 | finance.yahoo.comNeovasc Announces Fourth Quarter and Fiscal Year 2022 Financial Results and Provides Corporate UpdateMarch 9, 2023 | finance.yahoo.comNeovasc's (TSE:NVCN) investors will be pleased with their solid 171% return over the last yearMarch 6, 2023 | finance.yahoo.comNeovasc Shareholders Approve Acquisition by Shockwave MedicalFebruary 1, 2023 | finance.yahoo.comNeovasc Announces German Reimbursement RenewalJanuary 11, 2023 | finance.yahoo.comNeovasc (NVCN) is on the Move, Here's Why the Trend Could be SustainableApril 25, 2024 | Wall Street Star (Ad)AI finds its first serious applicationAI has infiltrated so many sectors, it's sent the demand for AI-friendly GPU computer chips rocketing. Nvidia has gone up more than 3x in the past year. It is now valued well over $2 trillion, making it one of the largest companies in the world.December 26, 2022 | finance.yahoo.comRecent Price Trend in Neovasc (NVCN) is Your Friend, Here's WhyDecember 21, 2022 | finance.yahoo.com3 Medical Instruments Stocks on Recovery Path After Dismal 2022November 28, 2022 | finance.yahoo.comNeovasc Announces Progress on COSIRA-II Clinical TrialNovember 17, 2022 | finance.yahoo.comNeovasc Third Quarter 2022 Earnings: Misses ExpectationsNovember 10, 2022 | finance.yahoo.comNeovasc Announces Third Quarter Financial Results and Provides Corporate UpdateOctober 27, 2022 | finance.yahoo.comNeovasc to Report Third Quarter Financial Results on November 10, 2022September 30, 2022 | proactiveinvestors.comNeovasc uses conference to announce positive interim clinical data from Neovasc Reducer use - Proactive Investors USASeptember 20, 2022 | streetinsider.comForm 6-K NEOVASC INC For: Sep 20 - StreetInsider.comSeptember 20, 2022 | seekingalpha.comNeovasc puts further development of its Tiara transcatheter treatment on hold - Seeking AlphaSeptember 20, 2022 | globenewswire.comNeovasc Provides Corporate Update Following Clinical Data Release - GlobeNewswireSeptember 17, 2022 | finance.yahoo.comNeovasc to Participate in LSI Europe 2022 Emerging MedTech Summit - Yahoo FinanceSeptember 16, 2022 | globenewswire.comNeovasc to Participate in LSI Europe 2022 Emerging MedTech Summit - GlobeNewswireSeptember 15, 2022 | globenewswire.comNeovasc Comments on New ICD-10-CM Diagnosis Codes for Refractory Angina - GlobeNewswireSeptember 15, 2022 | finance.yahoo.comNeovasc Comments on New ICD-10-CM Diagnosis Codes for Refractory AnginaSeptember 8, 2022 | marketscreener.comNeovasc Announces Participation at Transcatheter Cardiovascular Therapeutics Conf - Marketscreener.comSeptember 8, 2022 | finance.yahoo.comScaleFlux Announces Partnership with TD SYNNEX to Increase Market Footprint for Next-generation SSDs - Yahoo FinanceSeptember 8, 2022 | finance.yahoo.com32 Shipping Companies Presenting at Capital Link’s 14th Annual New York Maritime Forum September 21, 2022 in New York City - Yahoo FinanceSeptember 8, 2022 | globenewswire.comNeovasc Announces Key Events at TCT 2022 - GlobeNewswireSee More Headlines Receive NVCN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Neovasc and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/09/2021Today4/25/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Surgical & medical instruments Sub-IndustryN/A Current SymbolNASDAQ:NVCN CUSIPN/A CIK1399708 Webwww.neovasc.com Phone(604) 270-4344Fax604-270-4384Employees49Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($15.08) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-41,200,000.00 Net Margins-1,082.92% Pretax Margin-1,082.26% Return on Equity-127.25% Return on Assets-80.31% Debt Debt-to-Equity Ratio0.80 Current Ratio2.96 Quick Ratio2.85 Sales & Book Value Annual Sales$3.81 million Price / Sales21.60 Cash FlowN/A Price / Cash FlowN/A Book Value$5.77 per share Price / Book5.20Miscellaneous Outstanding Shares2,740,000Free FloatN/AMarket Cap$82.28 million OptionableNot Optionable Beta1.70 7 Stocks to Buy And Hold ForeverClick the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report Key ExecutivesFredericus Antonius ColenPresident, Chief Executive Officer & DirectorBill LittleChief Operating OfficerChristopher ClarkChief Financial Officer & SecretarySarah GallagherVice President-Clinical AffairsShmuel BanaiMedical DirectorKey CompetitorsBrainsWayNASDAQ:BWAYAllurion TechnologiesNYSE:ALURenVVeno MedicalNASDAQ:NVNOMonogram OrthopaedicsNASDAQ:MGRMBlueRiver AcquisitionNYSE:BLUAView All Competitors NVCN Stock Analysis - Frequently Asked Questions How were Neovasc's earnings last quarter? Neovasc Inc. (NASDAQ:NVCN) released its quarterly earnings results on Tuesday, November, 9th. The medical equipment provider reported ($2.75) earnings per share (EPS) for the quarter, missing the consensus estimate of ($2.25) by $0.50. The medical equipment provider had revenue of $0.70 million for the quarter, compared to the consensus estimate of $1.20 million. Neovasc had a negative trailing twelve-month return on equity of 127.25% and a negative net margin of 1,082.92%. During the same quarter in the previous year, the business posted ($12.75) EPS. When did Neovasc's stock split? Neovasc shares reverse split on the morning of Friday, April 29th 2022. The 1-25 reverse split was announced on Friday, April 29th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Friday, April 29th 2022. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split. What other stocks do shareholders of Neovasc own? Based on aggregate information from My MarketBeat watchlists, some companies that other Neovasc investors own include Biopharmx (BPMX), Allstate (ALL), Amicus Therapeutics (FOLD), Synergy Pharmaceuticals (SGYP), Rexahn Pharmaceuticals (REXN), Heat Biologics (HTBX), Palatin Technologies (PTN), Amarin (AMRN). This page (NASDAQ:NVCN) was last updated on 4/25/2024 by MarketBeat.com Staff From Our PartnersThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThese AI trades triggered this morning (545% return)Prosper Trading AcademyThe A.I. story nobody is telling you (Read ASAP)TradeSmithHe Is Giving Away BitcoinCrypto Swap ProfitsFed launches fourth dollar overhaulStansberry ResearchThe only accurate crypto trading system I know …Weiss RatingsBitcoin Rockets To Record High But Buy THIS InsteadParadigm Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Neovasc Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
